Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity
Authors:
- Michael A. MaurerMMMichael A. Maurer
- Goran RakocevicGRGoran Rakocevic
- Carol S. LeungCLCarol S. Leung
- Isaak QuastIQIsaak Quast
- Martin LukačišinMLMartin Lukačišin
- Norbert GoebelsNGNorbert Goebels
- Christian MünzChristian Münz
- Hedda WardemannHWHedda Wardemann
- Marinos DalakasMDMarinos Dalakas
- Jan D. LünemannJLJan D. Lünemann
- 2 April 2012
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (4) , 1393-1402
Abstract
The B cell–depleting IgG1 monoclonal antibody rituximab can persistently suppress disease progression in some patients with autoimmune diseases. However, the mechanism underlying these long-term beneficial effects has remained unclear. Here, we evaluated Ig gene usage in patients with anti–myelin-associated glycoprotein (anti-MAG) neuropathy, an autoimmune disease of the peripheral nervous system that is mediated by IgM autoantibodies binding to MAG antigen. Patients with anti-MAG neuropathy showed substantial clonal expansions of blood IgM memory B cells that recognized MAG antigen. The group of patients showing no clinical improvement after rituximab therapy were distinguished from clinical responders by a higher load of clonal IgM memory B cell expansions before and after therapy, by persistence of clonal expansions despite efficient peripheral B cell depletion, and by a lack of substantial changes in somatic hypermutation frequencies of IgM memory B cells. We infer from these data that the effectiveness of rituximab therapy depends on efficient depletion of noncirculating B cells and is associated with qualitative immunological changes that indicate reconfiguration of B cell memory through sustained reduction of autoreactive clonal expansions. These findings support the continued development of B cell–depleting therapies for autoimmune diseases.Keywords
This publication has 39 references indexed in Scilit:
- IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide SequencesCold Spring Harbor Protocols, 2011
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals of the Rheumatic Diseases, 2008
- IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysisNucleic Acids Research, 2008
- Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPGJournal of Neuroimmunology, 2008
- Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloningJournal of Immunological Methods, 2008
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin MJournal of the Peripheral Nervous System, 2007
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006
- Anti-myelin-associated glycoprotein neuropathyCurrent Opinion in Neurology, 2006
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001